Published in Eur J Pharmacol on March 31, 2000
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest (2003) 3.62
Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol (2002) 2.54
Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol (2001) 2.07
The endocannabinoid system in brain reward processes. Br J Pharmacol (2008) 1.71
Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron (2005) 1.58
Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav (2007) 1.22
The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine. Psychopharmacology (Berl) (2003) 0.88
The inhibitory effect of anandamide on luteinizing hormone-releasing hormone secretion is reversed by estrogen. Proc Natl Acad Sci U S A (2004) 0.88
Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats. Psychopharmacology (Berl) (2007) 0.88
A potential function of endocannabinoids in the selection of a navigation strategy by rats. Psychopharmacology (Berl) (2007) 0.83
The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB₁- and FAAH-independent mechanisms. Br J Pharmacol (2013) 0.81
Noladin ether, a putative endocannabinoid, enhances motivation to eat after acute systemic administration in rats. Br J Pharmacol (2012) 0.80
Fish oil promotes survival and protects against cognitive decline in severely undernourished mice by normalizing satiety signals. J Nutr Biochem (2010) 0.79
Endocannabinoid Regulation of Reward and Reinforcement through Interaction with Dopamine and Endogenous Opioid Signaling. Neuropsychopharmacology (2017) 0.78
The endocannabinoid anandamide during lactation increases body fat content and CB1 receptor levels in mice adipose tissue. Nutr Diabetes (2015) 0.78
The endocannabinoid system: role in energy regulation. Pediatr Blood Cancer (2012) 0.77
Quantitative analysis of performance on a progressive-ratio schedule: effects of reinforcer type, food deprivation and acute treatment with Δ⁹-tetrahydrocannabinol (THC). Behav Processes (2015) 0.77
Cannabis constituents modulate δ9-tetrahydrocannabinol-induced hyperphagia in rats. Psychopharmacology (Berl) (2010) 0.76
Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics (2016) 0.76
Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. Psychopharmacology (Berl) (2012) 0.76
Mice Expressing a "Hyper-Sensitive" Form of the Cannabinoid Receptor 1 (CB1) Are Neither Obese Nor Diabetic. PLoS One (2016) 0.76
CB1 Receptors Signaling in the Brain: Extracting Specificity from Ubiquity. Neuropsychopharmacology (2017) 0.75
Rimonabant abolishes sensitivity to workload changes in a progressive ratio procedure. Pharmacol Biochem Behav (2012) 0.75
Association of the c.385C>A (p.Pro129Thr) polymorphism of the fatty acid amide hydrolase gene with anorexia nervosa in the Japanese population. Mol Genet Genomic Med (2014) 0.75
Leptogenic effects of N-acyl-phosphatidylethanolamine (NAPE) requires activity of N-acylphosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD). J Lipid Res (2017) 0.75
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature (2001) 3.33
Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav (1991) 2.57
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther (1994) 2.55
Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology (1980) 2.41
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A (1999) 2.32
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol (2001) 2.15
Marihuana chemistry. Science (1970) 2.10
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem (1997) 2.01
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (2000) 1.96
Chemical basis of hashish activity. Science (1970) 1.94
2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A (2001) 1.86
Variation in plasma calcium with induced changes in plasma specific gravity, total protein, and albumin. Br Med J (1973) 1.83
An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol (1998) 1.83
Early medical use of cannabis. Nature (1993) 1.80
Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol (1993) 1.73
Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res (2011) 1.60
Discovery and characterization of endogenous cannabinoids. Life Sci (1999) 1.56
Anandamide may mediate sleep induction. Nature (1997) 1.53
Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol (1997) 1.49
The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc (1971) 1.44
Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem (1993) 1.44
Breast-fed and formula-fed infants do not differ in immunocompetent cell cytokine production despite differences in cell membrane fatty acid composition. Am J Clin Nutr (2000) 1.44
Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol (1992) 1.44
Biphasic effects of anandamide. Pharmacol Biochem Behav (1998) 1.41
Empirical comparison of two psychological therapies. Self psychology and cognitive orientation in the treatment of anorexia and bulimia. J Psychother Pract Res (1999) 1.40
Nutrition and quality of life in the aged: the Jerusalem 70-year olds longitudinal study. Aging (Milano) (2000) 1.40
Recent advances in the chemistry of hashish. Fortschr Chem Org Naturst (1967) 1.40
Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia (2007) 1.33
The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett (1967) 1.30
A critical investigation into the antibiotic sterilization of heart valve homografts. Thorax (1974) 1.26
Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity (2006) 1.22
The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett (1995) 1.20
An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci (1995) 1.20
Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem (1993) 1.20
Pharmacological effects of two active constituents of marihuana. Arch Int Pharmacodyn Ther (1968) 1.18
Toward drugs derived from cannabis. Naturwissenschaften (1978) 1.17
A novel probe for the cannabinoid receptor. J Med Chem (1992) 1.16
Stereochemical effects of 11-OH-delta 8-THC-dimethylheptyl in mice and dogs. Pharmacol Biochem Behav (1989) 1.15
(-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem (1996) 1.15
Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem (1997) 1.15
Polymyxin B reduces total parenteral nutrition-associated hepatic steatosis by its antibacterial activity and by blocking deleterious effects of lipopolysaccharide. JPEN J Parenter Enteral Nutr (1993) 1.14
2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur J Pharmacol (2000) 1.13
Anandamide (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. Proc Natl Acad Sci U S A (1994) 1.13
Antipsychotic effect of cannabidiol. J Clin Psychiatry (1995) 1.13
Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol (2012) 1.11
Release of prostaglandin E2 and unidentified factors from ventilated lungs. Br J Surg (1971) 1.07
Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. J Control Release (2003) 1.06
Suppressors of cancer cell proliferation from fig (Ficus carica) resin: isolation and structure elucidation. J Nat Prod (2001) 1.05
Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron (1965) 1.05
A study investigating the acute dose-response effects of 13 mg and 17 mg Delta 9- tetrahydrocannabinol on cognitive-motor skills, subjective and autonomic measures in regular users of marijuana. J Psychopharmacol (2008) 1.02
Identification through synthesis of an active delta-1(6)-tetrahydrocannabinol metabolite. J Am Chem Soc (1970) 1.02
Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-hydroxy-delta 8-tetrahydrocannabinol in rats and pigeons. J Pharmacol Exp Ther (1989) 1.02
Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol (2001) 1.01
Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities. J Med Chem (1992) 1.01
The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. Biochem Biophys Res Commun (1997) 1.00
Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat. J Surg Res (1991) 0.99
Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology (1990) 0.99
Lipoprotein secretion by isolated perfused livers from streptozotocin-diabetic rats. Diabetologia (1981) 0.99
The chemistry of endocannabinoids. J Endocrinol Invest (2006) 0.99
Carcinoid myopathy and treatment with cyproheptadine (Periactin). Gut (1974) 0.97
Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology (1995) 0.97
Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice. Br J Pharmacol (2011) 0.96
A stereospecific synthesis of (-)-delta 1- and (-)-delta 1(6)-tetrahydrocannabinols. J Am Chem Soc (1967) 0.96
Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharmacol (2011) 0.96
Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J Pharmacol Exp Ther (1997) 0.95
Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. Mol Hum Reprod (2004) 0.95
Syntheses of 1 -tetrahydrocannabinol and related cannabinoids. J Am Chem Soc (1972) 0.94
Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol (1994) 0.94
Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc Natl Acad Sci U S A (1989) 0.93
Stability of red blood cell membrane fatty acid composition after acute myocardial infarction. J Clin Epidemiol (1995) 0.93
Endothelial-mediated regulation of cerebral microcirculation. J Physiol Pharmacol (2006) 0.93
Hereditary spherocytosis, haemochromatosis, diabetes mellitus and chondrocalcinosis. Proc R Soc Med (1973) 0.93
Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation. Br J Pharmacol (2010) 0.93
Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice. Behav Pharmacol (2005) 0.92
Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology (1994) 0.92
Association study of cannabinoid receptor gene (CNR1) alleles and anorexia nervosa: differences between restricting and binging/purging subtypes. Am J Med Genet B Neuropsychiatr Genet (2004) 0.92
Alterations in adipocyte free fatty acid re-esterification associated with obesity and weight reduction in man. Am J Clin Nutr (1985) 0.92
Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol (1982) 0.91
Poststreptococcal neprhitis and acute rheumatic fever in two adults. Arch Intern Med (1985) 0.91
A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. J Neurotrauma (1993) 0.91
Human brain capillary endothelium: 2-arachidonoglycerol (endocannabinoid) interacts with endothelin-1. Circ Res (2000) 0.91
Towards cannabinoid drugs. Prog Med Chem (1987) 0.90
Role of the liver in the degradation of very low density lipoproteins: a study of lipolysis by heparin releasable liver lipase and uptake during isolated rat liver perfusion. Eur J Clin Invest (1981) 0.90
Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur J Pharmacol (1995) 0.89
Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress. Cell Death Dis (2012) 0.89
Separation as a new animal model for self-induced weight loss. Physiol Behav (1997) 0.89
Evaluation of plasma low molecular weight antioxidant capacity by cyclic voltammetry. Free Radic Biol Med (1997) 0.89
Refusal to eat in the elderly. Nutr Rev (1998) 0.88
Overall low molecular weight antioxidant activity of biological fluids and tissues by cyclic voltammetry. Methods Enzymol (1999) 0.88
Treatment of acute hepatic encephalopathy with L-dopa. Postgrad Med J (1977) 0.88
Diet and lifestyle in managing postmenopausal obesity. Climacteric (2007) 0.88
Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther (1995) 0.88
Synthesis and biological activity of five tetrahydrocannabinol metabolites. J Am Chem Soc (1972) 0.87
PADMA-28, a traditional tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants and pro-inflammatory agonists and peroxidation of lipids. Inflammopharmacology (1999) 0.87